Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise in shrinking stomach tumors before surgery

NCT ID NCT05507658

Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of the immunotherapy drug tislelizumab and chemotherapy (XELOX) given before surgery to 28 people with locally advanced stomach or gastroesophageal junction cancer. The goal was to see if this approach could shrink tumors more effectively and be safe. Results help explore a new treatment option for this type of cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

28 people

The number who actually took part.

Started

Jul 2022

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily sign the informed consent; 2. Aged 18-80 (including 18 and 80), both sexes; 3. ECOG score ≤1; 4. Biopsy histologically confirmed adenocarcinoma (including Lauren grade); 5. cT3-4a N+ M0 G/GEJ adenocarcinoma confirmed by basic ultrasound gastroscopy, enhanced CT (PET/CT), MRI or diagnostic laparoscopy; Exclusion Criteria: 1. Histological histological diagnosis of squamous cell carcinoma (adenosquamous carcinoma mainly including squamous cell carcinoma), carcinoid, undifferentiated carcinoma or other unclassified carcinoma; 2. Patients with HER2-positive status are excluded; 3. Patients with distant metastases other than primary gastric cancer (any M1 stage); 4. Patients with contraindications (laparoscopic surgery, open surgery, neoadjuvant chemotherapy); 5. Patients who can not undergo radical surgical resection (D2 radical resection); 6. Previous antitumor therapy (including chemotherapy, radiotherapy, molecular targeted therapy and hormone therapy); 7. Previously received immunological drugs such as PD-1/PD-L1, CTLA-4 or other immunological or molecular targeted therapies; 8. When virological testing prior to screening showed any of the following: 1. patients with active hepatitis (HBV DNA≥1\*103 copies or ≥200IU/mL); 2. Anti - HCV positive; 3. HIV positive; 9. Patients or their families refused to sign this informed consent form to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroesophageal junction adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced gastric adenocarcinoma

Contacts and locations

Locations

  • Xijing Hospital of Digestive Diseases

    Xi'an, Shaanxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.